It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with HER2-Expressing Cancers

Clinical Trial Title: 
Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.
Clinical Trial Protocol ID: 
17051706
Clinical Trial Investigator Name: 
Melody A. Cobleigh, MD
Clinical Trial Protocol Description: 

To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have HER2-expressing cancer.
  • Have an ECOG of 0 or 1.
  • Have adequate renal function.
  • Are at least 18 years of age.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-2993
Contact Name: 
Chelsea McPeek, RN